Optimizing current treatment of gout

Nature Reviews Rheumatology

Volumn 10, Issue 5, 2014, Pages 271-283

  Rees, Frances ^a   Hui, Michelle ^a   Doherty, Michael ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BIOLOGICAL PRODUCT; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; ASCORBIC ACID; BENZBROMARONE; CANAKINUMAB; DICLOFENAC; INDOMETACIN; LESINURAD; NAPROXEN; PLACEBO; PREDNISOLONE; PROBENECID; RILONACEPT; SULFINPYRAZONE; TENOXICAM; TRIAMCINOLONE ACETONIDE; ULODESINE; URATE;

ATTITUDE TO ILLNESS; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG COST; DRUG EFFICACY; GOUT; HEALTH CARE QUALITY; HOLISTIC CARE; HUMAN; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT EDUCATION; PERSONALIZED MEDICINE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROPHYLAXIS; REVIEW; RISK FACTOR; URATE LOWERING THERAPY; URIC ACID BLOOD LEVEL; CEREBROVASCULAR ACCIDENT; DIARRHEA; DRESS SYNDROME; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; HEART INFARCTION; HEPATITIS; KIDNEY FAILURE; LOADING DRUG DOSE; LOW DRUG DOSE; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; VOMITING; ANTAGONISTS AND INHIBITORS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; GOUT; HUMANS; URIC ACID;

EID: 84899927416     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.32     Document Type: Review

References (135)

1. Kuo, C. F., Grainge, M. J., Mallen, C., Zhang, W. & Doherty, M. Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann. Rheum. Dis. http://dx.doi.org/10.1136/ annrheumdis 2013 204463
2. Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 63, 3136-3141 (2011
3. Kuo, C. F. et al. Risk of myocardial infarction among patients with gout: A nationwide population-based study. Rheumatology (Oxford) 52, 111-117 (2013
4. Roddy, E., Zhang, W. & Doherty, M. Are joints affected by gout also affected by osteoarthritis? Ann. Rheum. Dis. 66, 1374-1377 (2007
5. Palmer, T. M. et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. BMJ 347, f4262 (2013
6. Stack, A. G., Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106, 647-658 (2013
7. Holme, I., Aastveit, A. H., Hammar, N., Jungner, I. & Walldius, G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417, 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med. 266, 558-570 (2009
8. Jolly, S. E. et al. Uric acid, hypertension, and chronic kidney disease among Alaska Eskimos: The Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN) study. J. Clin. Hypertens. 14, 71-77 (2012
9. Gnanenthiran, S. R., Hassett, G. M., Gibson, K. A. & McNeil, H. P. Acute gout management during hospitalization: A need for a protocol. Intern. Med. J. 41, 610-617 (2011
10. Roddy, E., Mallen, C. D., Hider, S. L. & Jordan, K. P. Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 49, 105-111 (2010
11. Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312-1324 (2006
12. Jordan, K. et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46, 1372-1374 (2007
13. Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken) 64, 1431-1446 (2012
14. Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. (Hoboken) 64, 1447-1461 (2012
15. Mikuls, T. R. et al. Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 64, 267-272 (2005
16. Garcia De La Torre, I. Double-blind parallel study comparing tenoxicam and placebo in acute gouty arthritis [Spanish]. Invet. Med. Int. 14, 92-97 (1987
17. Altman, R. D., Honig, S., Levin, J. M. & Lightfoot, R. W. Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study. J. Rheumatol. 15, 1422-1426 (1988
18. Butler, R. C. et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br. J. Clin. Pharmacol. 20, 511-513 (1985
19. Shrestha, M. et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann. Emerg. Med. 26, 682-686 (1995
20. Lederman, R. A double-blind comparison of etodolac and high doses of naproxen in the treatment of acute gout. Adv. Ther. 7, 344-354 (1990
21. Maccagno, A., Di Giorgio, E. & Romanowicz, A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr. Med. Res. Opin. 12, 423-429 (1991
22. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National clinical guideline for care and management in adults (Royal College of Physicians, London, 2008
23. Brater, D. C. Anti-inflammatory agents and renal function. Semin. Arthritis Rheum. 32 (Suppl. 1), 33-42 (2002
24. Rubin, B. R. et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum. 50, 598-606 (2004
25. Schumacher, H. R. Jr et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 324, 1488-1492 (2002
26. Chen, L. & Ashcroft, D. Risk of myocardial infarction associated with selective COX 2 inhibitors: Meta-Analysis of randomised controlled trials. Pharmacoepidemiol. Drug Saf. 16, 762-772 (2007
27. Terkeltaub, R. A. Colchicine update: 2008. Semin. Arthritis Rheum. 38, 411-419 (2009
28. Ahern, M. J. et al. Does colchicine work? The results of the first controlled study in acute gout. Aust. NZ J. Med. 17, 301-304 (1987
29. Terkeltaub, R. A. et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty four hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 62, 1060-1068 (2010
30. Terkeltaub, R. A. et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 63, 2226-2237 (2011
31. Clive, D. M. Renal transplant-Associated hyperuricemia and gout. J. Am. Soc. Nephrol. 11, 974-979 (2000
32. US Food and Drug Administration. Information for healthcare professionals: New safety information for colchicine (marketed as Colcrys) [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174315.htm (2009
33. Fernández, C., Noguera, R., González, J. A. & Pascual, E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J. Rheumatol. 26, 2285-2286 (1999
34. Courtney, P. & Doherty, M. Joint aspiration and injection and synovial fluid analysis. Best Pract. Res. Clin. Rheumatol. 23, 161-192 (2009
35. Janssens, H. J., Janssen, M., van De Lisdonk, E. H., van Riel, P. L. & van Weel, C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet 371, 1854-1860 (2008
36. Man, C. Y., Cheung, I. T., Cameron, P. A. & Rainer, T. H. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: A double-blind, randomized, controlled trial. Ann. Emerg. Med. 49, 670-677 (2007
37. Alloway, J. A., Moriarty, M. J., Hoogland, Y. T. & Nashel, D. J. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J. Rheumatol. 20, 111-113 (1993
38. Choy, E. H., Kingsley, G. H., Khoshaba, B., Pipitone, N. & Scott, D. L. Intramuscular Methylprednisolone Study Group. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann. Rheum. Dis. 64, 1288-1293 (2005
39. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL 1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007
40. Chen, K., Fields, T., Mancuso, C. A., Bass, A. R. & Vasanth, L. Anakinra's efficacy is variable in refractory gout: Report of ten cases. Semin. Arthritis Rheum. 40, 210-214 (2010
41. Schlesinger, N. et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult to treat gouty arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res. Ther. 13, R53 (2011
42. So, A. et al. Canakinumab for the treatment of acute flares in difficult to treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62, 3064-3076 (2010
43. Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71, 1839-1848 (2012
44. Terkeltaub, R. et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 68, 1613-1617 (2009
45. Schumacher, H. R. Jr et al. Rilonacept (interleukin 1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 64, 876-884 (2012
46. Schumacher, H. R. Jr et al. Rilonacept (interleukin 1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res. 64, 1462-1470 (2012
47. Schlesinger, N. et al. Local ice therapy during bouts of acute gouty arthritis. J. Rheumatol. 29, 331-334 (2002
48. Gambaro, G. & Perazella, M. A. Adverse renal effects of anti-inflammatory agents: Evaluation of selective and nonselective cyclooxygenase inhibitors. J. Intern. Med. 253, 643-652 (2003
49. Stamp, L. K. & Jordan, S. The challenges of gout management in the elderly. Drugs Aging 28, 591-603 (2011
50. Cattermole, G. N., Man, C. Y., Cheng, C. H., Graham, C. A. & Rainer, T. H. Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis. Eur. J. Emerg. Med. 16, 261-266 (2009
51. Wertheimer, A. I., Davis, M. W. & Lauterio, T. J. A new perspective on the pharmacoeconomics of colchicine. Curr. Med. Res. Opin. 27, 931-937 (2011
52. Arthritis Research UK. Gout [online], http://www.arthritisresearchuk.org/ arthritis-information/conditions/gout.aspx (2013
53. Rees, F., Jenkins, W. & Doherty, M. Patients with gout adhere to curative treatment if informed appropriately: Proof of concept observational study. Ann. Rheum. Dis.72, 826-830 (2013
54. Spencer, K., Carr, A. & Doherty, M. Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann. Rheum. Dis. 71, 1490-1495 (2012
55. Dalbeth, N. et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res. (Hoboken) 63, 1605-1612 (2011
56. Lindsay, K., Gow, P., Vanderpyl, J., Logo, P. & Dalbeth, N. The experience and impact of living with gout: A study of men with chronic gout using a qualitative grounded theory approach. J. Clin. Rheumatol. 17, 1-6 (2011
57. Harrold, L. R. et al. Patients' knowledge and beliefs concerning gout and its treatment: A population based study. BMC Musculoskelet. Disord. 13, 180 (2012
58. Choi, H. K., Atkinson, K., Karlson, E. W. & Curhan, G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The Health Professionals Follow-up Study. Arch. Intern. Med. 165, 742-748 (2005
59. Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W. & Curhan, G. Alcohol intake and risk of incident gout in men: A prospective study. Lancet. 363, 1277-1281 (2004
60. Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W. & Curhan, G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N. Engl. J. Med. 350, 1093-1103 (2004
61. Choi, H. K. & Curhan, G. Soft drinks, fructose consumption, and the risk of gout in men: Prospective cohort study. BMJ 336, 309-312 (2008
62. Choi, W. J., Ford, E. S., Curhan, G., Rankin, J. I. & Choi, H. K. Independent association of serum retinol and ? carotene levels with hyperuricemia: A national population study. Arthritis Care Res. (Hoboken) 64, 389-396 (2012).
63. Lyngdoh, T. et al. Serum uric acid and adiposity: Deciphering causality using a bidirectional Mendelian randomization approach. PLoS ONE 7, e39321 (2012
64. Joosten, L. A. B. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin 1 production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248 (2010
65. Dalbeth, N. et al. Identification of dairy fractions with antiinflammatory properties in models of acute gout. Ann. Rheum. Dis. 69, 766-769 (2010
66. Dalbeth, N. et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: A proof of concept randomised controlled trial. Ann. Rheum. Dis. 71, 929-934 (2012
67. Zhang, Y. et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 64, 4004-4011 (2012
68. Choi, H. K., Soriano, L. C., Zhang, Y. & Rodríguez, L. A. G. Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study. BMJ 344, d8190 (2012
69. Kaya, E. B. et al. Serum uric acid levels predict the severity and morphology of coronary atherosclerosis detected by multidetector computed tomography. Atherosclerosis 213, 178-183 (2010
70. Grayson, P. C., Kim, S. Y., Lavalley, M. & Choi, H. K. Hyperuricemia and incident hypertension: A systematic review and meta-Analysis. Arthritis Care Res. (Hoboken) 63, 102-110 (2011
71. Numata, T., Miyatake, N., Wada, J. & Makino, H. Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res. Clin. Pract. 80, e1-e5 (2008
72. Li, C., Hsieh, M. C. & Chang, S. J. Metabolic syndrome, diabetes, and hyperuricaemia. Curr. Opin. Rheumatol. 25, 210-216 (2013
73. Stamp, L. K. & Chapman, P. T. Gout and its comorbidities: Implications for therapy. Rheumatology (Oxford) 52, 34-44 (2013
74. Perez-Ruiz, F. Treating to target: A strategy to cure gout. Rheumatology (Oxford) 48 (Suppl. 2), ii9-ii14 (2009).
75. Perez-Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero-Beites, A. M. & Ruibal, A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 47, 356-360 (2002
76. De Miguel, E. et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: A pilot ultrasound study. Ann. Rheum. Dis. 71, 157-158 (2012
77. Pineda, C. et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: An ultrasound controlled study. Arthritis Res. Ther. 13, R4 (2011
78. Choi, H. K. et al. Dual energy CT in gout: A prospective validation study. Ann. Rheum. Dis. 71, 1466-1471 (2012
79. Pascual, E. Persistence of monosodium urate crystals and low grade inflammation in the synovial fluid of untreated gout. Arthritis Rheum. 34, 141-145 (1991
80. Taylor, T., Mecchella, J., Larson, R., Kerin, K. & MacKenzie, T. Initiation of allopurinol at first medical contact for acute attacks of gout: A randomized clinical trial. Am. J. Med. 125, 1126-1134 (2012
81. Reinders, M. K. et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann. Rheum. Dis. 68, 892-897 (2009
82. Kuzell, W. C., Seebach, L. M., Glover, R. P. & Jackman, A. E. Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone. Ann. Rheum. Dis. 25, 634-642 (1966
83. Bull, P. W. & Scott, J. T. Intermittent control of hyperuricemia in the treatment of gout. J. Rheumatol. 16, 1246-1248 (1989
84. Schumacher, H. R. Jr et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540-1548 (2008
85. Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450-2461 (2005
86. Perez-Ruiz, F., Hernando, I., Villar, I. & Nolla, J. M. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: Another insight to allopurinol-related toxicity. J. Clin. Rheumatol. 11, 129-133 (2005
87. Vazquez-Mellado, J., Morales, E. M., Pacheco-Tena, C. & Burgos-Vargas, R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann. Rheum. Dis. 60, 981-983 (2001
88. Dalbeth, N., Kumar, S., Stamp, L. & Gow, P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J. Rheumatol. 33, 1646-1650 (2006
89. Stamp, L. K. et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 63, 412-421 (2011
90. Kim, S. C., Newcomb, C., Margolis, D., Roy, J. & Hennessy, S. Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study. Arthritis Care Res. (Hoboken) 65, 578-584 (2013
91. Yeo S. I. HLA B 5801: Utility and cost-effectiveness in the Asia-Pacific Region. Int. J. Rheum. Dis. 16, 254-257 (2013
92. Stamp, L. K. et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum. 64, 2529-2536 (2012
93. Doehner, W. et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 105, 2619-2624 (2002
94. Noman, A., Ang, D., Ogston, S., Lang, C. & Struthers, A. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomised, placebo controlled crossover trial. Lancet 375, 2161-2167 (2010
95. Goicoechea, M. et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 5, 1388-1393 (2010
96. Momeni, A., Shahidi, S., Seirafian, S., Taheri, S. & Kheiri, S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran. J. Kidney Dis. 4, 128-132 (2010
97. Neogi, T. et al. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum. 64, 327-338 (2012
98. Becker, M. A. et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty eight day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52, 916-923 (2005
99. Becker, M. A. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res. Ther. 12, R63 (2010
100. European Medicines Agency. Summary of product characteristics: Adenuric film-coated tablets [online], http://www.medicines.org.uk/emc/medicine/22830/SPC (2012
101. Abeles, A. M. Febuxostat hypersensitivity. J. Rheumatol. 39, 659 (2012
102. Chohan, S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J. Rheumatol. 38, 1957-1959 (2011
103. National Institute for Health and Care Excellence. Febuxostat for the management of hyperuricaemia in people with gout. NICE technology appraisal guidance 164 [online], http://www.nice.org.uk/guidance/TA164 (2008
104. Ogino, K. et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: A double-blind placebo-controlled crossover preliminary study. Circ. Heart Fail. 3, 73-81 (2010
105. Reinders, M. K. et al. Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann. Rheum. Dis. 68, 51-56 (2009
106. Scott, J. T. Comparison of allopurinol and probenecid. Ann. Rheum. Dis. 25, 623-626 (1966
107. Reinders, M. K., van Roon, E. N., Houtman, P. M., Brouwers, J. R. & Jansen, T. L. Biochemical effectiveness of allopurinol and allopurinol- probenecid in previously benzbromarone-treated gout patients. Clin. Rheumatol. 26, 1459-1465 (2007
108. Lee, M. H., Graham, G. G., Williams, K. M. & Day, R. O. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 31, 643-665 (2008
109. Zhu, X. et al. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: Results of a prospective, open, randomized, case-control study. Transplant. Proc. 41, 3736-3742 (2009
110. Huang, H. Y. et al. The effects of vitamin C supplementation on serum concentrations of uric acid: Results of a randomized controlled trial. Arthritis Rheum. 52, 1843-1847 (2005
111. Juraschek, S. P., Miller, E. R. 3rd & Gelber, A. C. Effect of oral vitamin C supplementation on serum uric acid: A meta-Analysis of randomized controlled trials. Arthritis Care Res. (Hoboken) 63, 1295-1306 (2011
112. Bastow, M. D., Durrington, P. N. & Ishola, M. Hypertriglyceridemia and hyperuricemia: Effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 37, 217-220 (1988
113. Stamp, L. K. et al. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout. A pilot randomized controlled trial. Arthritis Rheum. 65, 1636-1642 (2013
114. Sundy, J. S. et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 306, 711-720 (2011
115. Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S. & Hershfield, M. S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res. Ther. 8, R12 (2006
116. Krystexxa®( pegloticase) prescribing information. Savient Pharmaceuticals Inc. [online], http://krystexxa.com/hcp/pdf/KRYSTEXXA- Prescribing-Information.pdf (2014
117. Malaguarnera, M. et al. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin. Pharmacother. 10, 737-742 (2009
118. De Angelis, S. et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. Eur. Rev. Med. Pharmacol. Sci. 11, 179-184 (2007
119. Pui, C. H. et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. Clin. Oncol. 19, 697-704 (2001
120. Richette, P., Brière, C., Hoenen-Clavert, V., Loeuille, D. & Bardin, T. Rasburicase for tophaceous gout not treatable with allopurinol: An exploratory study. J. Rheumatol. 34, 2093-2098 (2007
121. Lasko, B. et al. RDEA594, a novel uricosuric agent, significantly reduced serum urate levels and was well tolerated in a phase 2a pilot study in hyperuricemic gout patients [abstract]. Arthritis Rheum. 60 (Suppl. 10), 1105 (2009
122. Becker, M. et al. BCX4208 combined with allopurinol increases response rates in patients with gout who fail to reach goal range serum urate on allopurinol alone: A randomized, double-blind, placebo-controlled trial [L10]. Presented at the 2011 ACR/ARHP Annual Scientific Meeting. 123.
123. Li-Yu, J. et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol. 28, 577-580 (2001
124. De Oliveira, E. P. & Burini, R. C. High plasma uric acid concentration: Causes and consequences. Diabetol. Metab. Syndr. 4, 12 (2012
125. Perez-Ruiz, F., Herrero-Beites, A. M. & Carmona, L. A two-stage approach to the treatment of hyperuricemia in gout: The 'dirty dish' hypothesis. Arthritis Rheum. 63, 4002-4006 (2011
126. Borstad, G. C. et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 31, 2429-2432 (2004
127. Wortmann, R., MacDonald, P., Hunt, B. & Jackson, R. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: Analysis of data from three phase III trials. Clin. Ther. 32, 2386-2397 (2010
128. Mikuls, T. R., Farrar, J. T., Bilker, W. B., Fernandes, S. & Saag, K. G. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: Results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 44, 1038-1042 (2005
129. Roddy, E., Zhang, W. & Doherty, M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann. Rheum. Dis. 66, 1311-1315 (2007
130. Doherty, M. et al. Gout: Why is this curable disease so seldom cured? Ann. Rheum. Dis. 71, 1765-1770 (2012
131. Lioté, F. & Choi, H. Managing gout needs more than drugs: 'Il faut le savoir-faire, l'Art et La manière'. Ann. Rheum. Dis. 72, 791-793 (2013
132. Harrold, L. R. et al. Primary care providers' knowledge, beliefs and treatment practices for gout: Results of a physician questionnaire. Rheumatology (Oxford) 52, 1623-1629 (2013
133. Owens, D., Whelan, B. & McCarthy, G. A survey of the management of gout in primary care. Ir. Med. J. 101, 147-149 (2008
134. General Medical Council. Tomorrow's doctors: outcomes and standards for undergraduate medical education (General Medical Council, London, 2009
135. British National Formulary. BNF [online] http://www.bnf.org/bnf/index.htm (2014